The stock of Glaxosmithkline Plc (NYSE:GSK) registered an increase of 2.96% in short interest. The average target price is 1,577.33GBX with three firms rating the company a strong buy, six analysts rating the stock a buy, 17 analyts rating the stock a hold, two firms rating the company to underperform, and finally zero firmsrating the company as sell.
Advertisement
Goldman Sachs also remains bullish on GSK, reiterating its “buy” stance on the company this week, with a price target of 1,800p. Deutsche Bank AG restated a “hold” rating and issued a GBX 1,540 ($19.98) target price on shares of GlaxoSmithKline plc in a research report on Friday, March 18th. One analyst has rated the stock with a sell rating, twelve have given a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the stock. Investors of record on Friday, May 13th will be paid a dividend of $0.549 per share. The ex-dividend date of this dividend is Thursday, May 12th.
Glaxosmithkline has a one-year low of 1,227.50GBX and a one-year high of 1,690.28GBX with a P/E ratio of 131 and has a total market value of 80.0B GBX.
Burberry on Monday announced the departure of chief executive Christopher Bailey as it reported a 3% drop in first quarter like-for-like (LFL) sales, which was less than the 5% fall the market had forecast. The stock was acquired at an average price of GBX 2,103 ($27.28) per share, for a total transaction of £504.72 ($654.72). The short interest to Glaxosmithkline Plc’s float is 0.23%. Hamilton Point Investment Advisors LLC now owns 33,846 shares of the pharmaceutical company’s stock worth $1,366,000 after buying an additional 3,350 shares during the last quarter.
Advertisement
AstraZeneca plc (AstraZeneca) is a biopharmaceutical company. The Company is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter (OTC) medicines and health-related consumer products. The Company focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in various therapy areas, including respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology, as well as in infection, neuroscience and gastrointestinal areas.
